Phase 1b

TAIPEI, Taiwan — August 25, 2026 Senhwa Biosciences announced that it has completed patient enrollment in its Phase 1b...

LAUSANNE, Switzerland, August 20, 2026 AC Immune SA announced positive preliminary Phase 1 clinical data for ACI-19764, its wholly...

VANCOUVER, British Columbia, August 13, 202 Eupraxia Pharmaceuticals Inc. reported new symptom-response data from the ongoing Phase 1b/2a portion...

MELBOURNE, Australia, August 12, 2026 Propanc Biopharma, Inc. highlighted the potential of its investigational proenzyme therapy PRP as a...

LA JOLLA, Calif., August 11, 2026 CalciMedica, Inc. reported its second-quarter 2026 financial results and provided updates across its...

MELBOURNE, Australia, August 6, 2026 Propanc Biopharma announced compelling preclinical and early translational findings for its lead investigational therapy...

LEXINGTON, Mass., August 6, 2026 Agenus Inc. reported its second-quarter 2026 financial results while outlining significant progress in advancing...

PARIS, Aug. 4, 2026 Evexta Bio announced a clinical trial collaboration and supply agreement with Roche to evaluate its...

Danbury, Conn. & Westlake Village, Calif., July 29, 2026 MannKind Corporation announced positive topline results from its Phase 1b...

Agoura Hills, Calif., July 22, 2026 Oncotelic Therapeutics and Sapu Nano announced the publication of a peer-reviewed study in...